Etanercept Therapy in Rheumatoid Arthritis

W. Moreland, Larry; H. Schiff, Michael; W. Baumgartner, Scott; A. Tindall, Elizabeth; M. Fleischmann, Roy; J. Bulpitt, Ken; L. Weaver, Arthur; C. Keystone, Edward; E. Furst, Daniel; J. Mease, Philip; M. Ruderman, Eric; A. Horwitz, David; G. Arkfeld, Daniel; Garrison, Leslie; J. Burge, Daniel; M. Blosch, Consuelo; L.M. Lange, Mary; D. McDonnell, Neil; E. Weinblatt, Michael

doi:10.7326/0003-4819-130-6-199903160-00004

Public

Etanercept Therapy in Rheumatoid Arthritis

Published in Annals of Internal Medicine • Mar 16, 1999

Authors:

Larry W. Moreland

Michael H. Schiff

Scott W. Baumgartner

Abstract

BACKGROUND: In a phase II study, etanercept (recombinant human tumor necrosis factor receptor [p75]:Fc fusion protein) safely produced rapid, dose-dependent improvement in rheumatoid arthritis over 3 months. OBJECTIVE: To confirm the benefit of etanercept therapy of longer duration and simplified do...

Subject

Etanercept

Medicine

Rheumatoid arthritis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!